---
title: "Taltz (ixekizumab) in plaque psoriasis: Drug interactions questions"
description: "Drug interactions questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Taltz have drug interactions? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Drug interactions questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications](https://www.evicenter.com/medical-information/taltz).

## Drug interactions

<a id="taltz-drug-interactions"></a>

### Does Taltz have drug interactions?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate) or midazolam (CYP3A substrate) were observed in subjects with plaque psoriasis when used concomitantly with a single 160 mg dose of ixekizumab, or multiple doses of 80 mg every 2 weeks. The potential effect of ixekizumab on the CYP2D6 activity cannot be ruled out due to high variability in exposure (approximately ±2-fold) of dextromethorphan and its CYP2D6 metabolite dextrorphan in psoriasis subjects.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=No%20clinically%20significant%20changes%20in,metabolite%20dextrorphan%20in%20psoriasis%20subjects.)

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines)
